Compare GFF & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFF | ACAD |
|---|---|---|
| Founded | 1959 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.3B |
| IPO Year | 1994 | 2000 |
| Metric | GFF | ACAD |
|---|---|---|
| Price | $97.59 | $27.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 22 |
| Target Price | ★ $105.00 | $30.55 |
| AVG Volume (30 Days) | 265.5K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.99% | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | ★ 2.97 | 0.20 |
| Revenue | ★ $2,519,926,000.00 | $726,437,000.00 |
| Revenue This Year | N/A | $18.80 |
| Revenue Next Year | N/A | $11.70 |
| P/E Ratio | ★ $33.56 | $140.10 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $65.01 | $19.69 |
| 52 Week High | $108.57 | $30.96 |
| Indicator | GFF | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 48.19 | 46.04 |
| Support Level | $88.43 | $27.90 |
| Resistance Level | $108.57 | $30.96 |
| Average True Range (ATR) | 2.42 | 0.81 |
| MACD | -0.72 | -0.35 |
| Stochastic Oscillator | 32.82 | 21.50 |
Griffon Corp manufactures and markets residential, commercial and industrial garage doors to professional installing dealers and home center retail chains. It also provides non-powered landscaping products for homeowners and professionals. Its operating segments include Consumer and Professional Products: is a provider of branded consumer and professional tools; residential, industrial and commercial fans; home storage and organization products; and Home and Building Products conducts its operations through Clopay Corporation (Clopay). Clopay is the manufacturer and marketer of garage doors and rolling steel doors in North America. The company generates a majority of its revenue from the Home and Building Products segment. Operates in USA, Europe, Canada, Australia, and Others.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.